Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Glecaprevir/Pibrentasvir (G/P) and Sofosbuvir (SOF) in Hepatitis C virus infection difficult to treat patients including DAA failure patients

Trial Profile

A clinical study of Glecaprevir/Pibrentasvir (G/P) and Sofosbuvir (SOF) in Hepatitis C virus infection difficult to treat patients including DAA failure patients

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 SVR12 data will be available for all patients in April 2018.
    • 05 Jun 2018 Results presented at the Digestive Disease Week 2018
    • 15 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top